Lineage Cell Therapeutics
LCTX
LCTX
109 hedge funds and large institutions have $151M invested in Lineage Cell Therapeutics in 2017 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 21 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $161M → $151M (-$9.93M)
27% less call options, than puts
Call options by funds: $112K | Put options by funds: $153K
Holders
109
Holding in Top 10
1
Calls
$112K
Puts
$153K
Top Buyers
| 1 | +$1.68M | |
| 2 | +$575K | |
| 3 | +$480K | |
| 4 |
Two Sigma Investments
New York
|
+$435K |
| 5 |
IA
IndexIQ Advisors
New York
|
+$431K |
Top Sellers
| 1 | -$1.77M | |
| 2 | -$357K | |
| 3 | -$221K | |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$196K |
| 5 |
Goldman Sachs
New York
|
-$179K |